Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF

NCT04739215 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Heart Failure With Preserved Ejection Fraction

Interventions

DRUG: Dapagliflozin 10 MG [Farxiga]
DRUG: Placebo

Sponsor

Hospital General Universitario Gregorio Marañon

Collaborators

[object Object]
[object Object]
[object Object]